Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the Unit… Read more
Synairgen plc - Asset Resilience Ratio
Synairgen plc (SYGGF) has an Asset Resilience Ratio of 10.55% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2023)
This chart shows how Synairgen plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Synairgen plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.50 Million | 10.55% |
| Total Liquid Assets | $1.50 Million | 10.55% |
Asset Resilience Insights
- Moderate Liquidity: Synairgen plc has 10.55% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Synairgen plc Industry Peers by Asset Resilience Ratio
Compare Synairgen plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Synairgen plc (2004–2023)
The table below shows the annual Asset Resilience Ratio data for Synairgen plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 10.55% | $1.50 Million | $14.22 Million | -5.39pp |
| 2022-12-31 | 15.94% | $3.75 Million | $23.53 Million | +15.20pp |
| 2018-12-31 | 0.73% | $50.00K | $6.80 Million | -25.37pp |
| 2017-12-31 | 26.10% | $2.00 Million | $7.66 Million | -3.85pp |
| 2016-12-31 | 29.95% | $1.66 Million | $5.54 Million | -14.98pp |
| 2015-12-31 | 44.94% | $3.72 Million | $8.28 Million | -23.05pp |
| 2014-12-31 | 67.99% | $6.75 Million | $9.93 Million | +45.49pp |
| 2013-12-31 | 22.50% | $458.00K | $2.04 Million | -15.09pp |
| 2012-12-31 | 37.59% | $1.43 Million | $3.81 Million | -18.22pp |
| 2010-12-31 | 55.81% | $2.70 Million | $4.84 Million | -25.33pp |
| 2009-12-31 | 81.13% | $6.14 Million | $7.57 Million | +58.32pp |
| 2008-12-31 | 22.81% | $1.98 Million | $8.67 Million | -49.38pp |
| 2007-12-31 | 72.19% | $3.44 Million | $4.77 Million | -2.12pp |
| 2006-12-31 | 74.31% | $5.00 Million | $6.73 Million | -16.93pp |
| 2005-12-31 | 91.24% | $7.46 Million | $8.18 Million | -1.91pp |
| 2004-12-31 | 93.15% | $8.61 Million | $9.24 Million | -- |